Table 3. Summary of covariate analysis: backward elimination.
Model | Covariate effect | ΔMVOF | Degrees of freedom | P value |
---|---|---|---|---|
10 | Healthy status on CL | −17.410 | 1 | – |
11 | Healthy status on V2 | −23.415 | 1 | <0.00001 |
12 | Healthy status on Q4 | −57.431 | 1 | <0.00001 |
13 | Healthy status on V4 | −50.314 | 1 | <0.00001 |
14 | Healthy status on D1 | −11.745 | 1 | 0.00061 |
15 | Healthy status on KA | −14.901 | 1 | 0.00011 |
16 | Liquid formulation on ALAG1 | −82.642 | 1 | <0.00001 |
17 | Liquid formulation on D1 | −42.831 | 1 | <0.00001 |
18 | Liquid formulation on KA | −36.299 | 1 | <0.00001 |
19 | WGT on V22 | −30.176 | 1 | <0.00001 |
20 | TBIL on CL | −9.894 | 1 | 0.00166 |
1Apart from the disease status and the formulation effect, the full model included the following covariate effects: AST and TBIL on CL, WGT and SEX on V2, WGT on F1 and CLCR on ALAG1
The power coefficient quantifying the effect of WGT on V2 was not statistically different from 1 (Δ MVOF = –1.748, d.f. = 1, P = 0.186). Δ MVOF Change in the minimum value of the objective function.